FierceBiotech announces annual "Fierce 15" winners of 2015

FierceBiotech announces annual "Fierce 15" winners of 2015

Washington, DC – September 30, 2015 – FierceBiotech today announced its annual "Fierce 15" list of the top privately held biotechnology companies of 2015.  FierceBiotech editors John Carroll and Damian Garde evaluated hundreds of companies before selecting this year's winners.  Those selected are identified as some of the most promising private biotechnology companies in the industry. 

"This year's Fierce 15 is a particularly young group of companies, part of a wave of innovative startups led by industry veterans and backed by experienced investors," said Garde.  "There's been a lot of back and forth about risk and research--and their rewards--around the biotech industry lately, making it all the more refreshing to look over a crop of companies focused on developing novel therapies for unmet needs."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition.  Fifteen privately held drug developers or platform biotech's with the potential to have a huge impact on the treatment of human diseases. 

The 2015 Fierce 15 winners are:

1.       Alector

2.       Arvinas

3.       Cell Medica

4.       CRISPR Therapeutics

5.       Denali Therapeutics

6.       Intellia Therapeutics

7.       MyoKardia

8.       NGM Bio

9.       Padlock Therapeutics

10.   Revolution Medicines

11.   SQZ Biotech

12.   Surface Oncology

13.   Syros Pharmaceuticals

14.   Unum Therapeutics

15.   Yumanity Therapeutics

An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

This is FierceBiotech's thirteenth annual Fierce 15 selection.  A complete list of "Fierce 15" companies can be found online at www.fiercebiotech.com/fierce15. 

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more.  More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories.  Signup is free at www.fiercebiotech.com/signup.

About FierceMarkets

FierceMarkets is a digital media publisher, reporting news and insight to three million business professionals in eight global industries that generate trillions of dollars in revenues every year.  We also serve the advertising/marketing needs of the companies and organizations that want to influence and do business with our professional audience.  Our portfolio features more than 100 digital publications and websites, plus a suite of editorial and content marketing products and services including webinars, e-books, whitepapers, directories and events.  FierceMarkets is a division of Questex Media Group, LLC.  For more information visit www.fiercemarkets.com. 

 

###

CONTACT:

Rebecca Friend

FierceBiotech

202-824-5050

[email protected]

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”